Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress. An exploratory analysis of the HERceptin Adjuvant (HERA; NCT00045032) trial investigated the benefits of ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

Despite the impact of the pandemic on cancer care, Perjeta grew 17% to CHF 2.9 billion ($3.2 billion) in the first nine months of 2020, now just fractionally behind Herceptin which declined 31% to ...

A 22-year-old LASU student is urgently seeking N15 million financial assistance as she battles an aggressive form of breast ...

Accord BioPharma, the speciality division of Intas Pharmaceuticals, has received US Food and Drug Administration (FDA) ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Cell and gene therapy: Dr. Jeff Hersh examines 25 years of technological advances In general, earlier stage cancers have ...

The Food and Drug Administration (FDA) has approved a 420mg dosage strength of Hercessi ™ (trastuzumab-strf), a biosimilar to Herceptin ® (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

"Neoadjuvant therapy” refers to supplemental cancer treatment you receive before your primary treatment. Adjuvant therapies, ...

To aid researchers in ADC development, BioIVT provides Ki67 staining procedures with pre-stained blocks and custom screens.

Collecting and storing comprehensive data on human biospecimens is essential for generating high-quality, reproducible ...